Amneal Pharmaceuticals Receives European Commission Marketing Authorization for Adcomfo® (omalizumab)
11/17/2026
Impact: 65
Healthcare
The European Commission granted marketing authorization for Amneal Pharmaceuticals’ Adcomfo® (omalizumab), a biosimilar to XOLAIR®, for eligible patients with severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Developed by Kashiv BioSciences with Alvotech, the approval follows a positive EMA committee opinion in September 2026 and UK authorization in March 2026. Amneal is continuing to seek U.S. regulatory approval; the article reports no financial results or stock-price impact.
AI summary, not financial advice
Share: